AU
UK
CA
US
IND
NZ
Last update at 2026-06-05T14:59:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | 1.57M | -0.74500M | -3.25200M | -0.95000M | -0.54600M |
| Minority interest | - | - | - | - | - |
| Net income | 1.57M | -0.32800M | -3.86000M | -11.33300M | -2.10400M |
| Selling general administrative | 6.12M | 5.29M | 4.75M | 4.44M | 3.64M |
| Selling and marketing expenses | - | 1.38M | 1.53M | 1.26M | 0.98M |
| Gross profit | 5.00M | 6.05M | 3.17M | 4.75M | 4.00M |
| Reconciled depreciation | 0.61M | 0.65M | 0.59M | 1.29M | - |
| Ebit | 1.58M | -0.72300M | -3.23900M | -0.92900M | -0.46800M |
| Ebitda | 2.20M | -0.07300M | -2.64800M | -0.38200M | 0.42M |
| Depreciation and amortization | 0.61M | 0.65M | 0.59M | 0.55M | 0.89M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -0.64000M | -0.53500M | -2.77900M | -0.58200M | -0.48800M |
| Other operating expenses | 8.97M | 10.31M | 10.32M | 9.13M | 7.28M |
| Interest expense | 0.02M | 0.02M | 0.01M | 0.02M | 0.08M |
| Tax provision | 0.00000M | -0.41700M | -0.08000M | 0.46M | - |
| Interest income | 0.15M | 0.05M | 0.00000M | - | - |
| Net interest income | 0.13M | 0.03M | -0.01300M | -0.02100M | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -0.41700M | -0.08000M | 0.46M | -0.93100M |
| Total revenue | 8.33M | 9.77M | 7.55M | 8.54M | 6.82M |
| Total operating expenses | 5.64M | 6.58M | 5.95M | 5.33M | 4.28M |
| Cost of revenue | 3.33M | 3.73M | 4.37M | 3.79M | 2.82M |
| Total other income expense net | 2.21M | -0.21000M | -0.47300M | -0.35800M | -0.07800M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1.57M | -0.32800M | -3.17200M | -1.40900M | - |
| Net income applicable to common shares | - | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 13.80M | 13.89M | 14.40M | 17.84M | 29.55M |
| Intangible assets | 0.80M | 1.08M | 1.51M | 1.73M | 6.88M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.20M | 0.12M | 0.07M | 5.20M | 0.13M |
| Total liab | 2.39M | 4.21M | 4.45M | 6.02M | 6.16M |
| Total stockholder equity | 11.41M | 9.68M | 9.95M | 11.82M | 23.38M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.13M | 0.83M | 0.97M | 2.40M | 1.26M |
| Common stock | 10.26M | 10.26M | 10.24M | 8.04M | 8.03M |
| Capital stock | 10.26M | 10.26M | 10.24M | 8.04M | - |
| Retained earnings | -23.83300M | -25.58500M | -25.31900M | -21.53700M | -9.89100M |
| Other liab | - | - | - | - | - |
| Good will | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M |
| Other assets | - | - | - | - | - |
| Cash | 4.87M | 2.94M | 5.12M | 1.60M | 5.83M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.12M | 1.69M | 1.94M | 3.44M | 3.05M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -4.51900M | -2.79500M | -5.04100M | -1.23500M | -2.98400M |
| Short term debt | 0.22M | 0.25M | 0.11M | 0.59M | 0.76M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.35M | 0.15M | 0.07M | 0.37M | 2.84M |
| Other stockholder equity | 25.07M | 25.01M | 25.03M | 25.31M | 25.29M |
| Property plant equipment | - | - | - | - | - |
| Total current assets | 7.66M | 7.88M | 8.29M | 10.74M | 12.24M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | - |
| Short term investments | - | 2.50M | - | - | - |
| Net receivables | 1.77M | 1.70M | 2.33M | 2.84M | 4.04M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.83M | 0.61M | 0.78M | 1.09M | 2.24M |
| Accounts payable | 0.77M | 0.61M | 0.85M | 0.45M | 1.03M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.08500M | - | - | - | -0.04100M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6.14M | 6.02M | 6.11M | 7.10M | 17.31M |
| Capital lease obligations | 0.35M | 0.15M | 0.07M | 0.37M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | 2.50M | -2.50100M | 0.00000M | - | - |
| Change to liabilities | - | - | - | - | - |
| Total cashflows from investing activities | 2.12M | -2.51000M | 5.18M | -0.49300M | -2.82500M |
| Net borrowings | -0.14000M | -0.14300M | -0.31400M | 0.00000M | - |
| Total cash from financing activities | -0.25100M | -0.26500M | 1.49M | -0.50200M | 11.07M |
| Change to operating activities | - | - | - | - | - |
| Net income | 1.57M | -0.32800M | -3.86000M | -11.33300M | -2.10400M |
| Change in cash | 1.93M | -2.17200M | 3.51M | -4.22200M | 5.83M |
| Begin period cash flow | 2.94M | 5.12M | 1.60M | 5.83M | - |
| End period cash flow | 4.87M | 2.94M | 5.12M | 1.60M | 5.83M |
| Total cash from operating activities | 0.08M | 0.61M | -3.15200M | -3.22900M | -2.41900M |
| Issuance of capital stock | - | 0.00000M | 2.20M | 0.07M | - |
| Depreciation | 0.61M | 0.65M | 0.59M | 1.29M | 0.89M |
| Other cashflows from investing activities | -0.00100M | 0.04M | -0.10900M | - | -0.86000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.22200M | 0.17M | 0.13M | 0.48M | -1.06900M |
| Change to account receivables | -0.14100M | 0.58M | 0.81M | 1.13M | -0.88700M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -0.11100M | -0.12200M | -0.40000M | -0.37200M | -0.21800M |
| Change to netincome | - | - | - | - | - |
| Capital expenditures | 0.22M | 0.06M | 0.15M | 1.48M | 2.83M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -2.29400M | 0.55M | -0.66500M | 1.47M | -0.88400M |
| Stock based compensation | 0.19M | 0.07M | 0.08M | 0.28M | 0.27M |
| Other non cash items | 0.20M | -0.33500M | 0.70M | 5.07M | -0.58700M |
| Free cash flow | -0.14200M | 0.55M | -3.30500M | -4.70700M | -5.24400M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CNSL Cambridge Nutritional Sciences plc |
- -% | 1.85 | 1.85 | 99.01 | 0.55 | 0.40 | 0.13 | 0.52 |
| CTEC ConvaTec Group PLC |
- -% | 204.20 | 37.27 | 14.66 | 1.79 | 3.77 | 2.94 | 13.89 |
| AMS Advanced Medical Solutions Group plc |
-4.0 1.81% | 217.00 | 40.60 | 16.84 | 1.92 | 1.66 | 2.16 | 11.16 |
| TSTL Tristel |
5.00 1.33% | 380.00 | 23.75 | 19.08 | 3.68 | 5.29 | 3.43 | 13.18 |
| SPEC Inspecs Group plc |
- -% | 84.50 | - | 16.16 | 0.43 | 0.95 | 0.62 | 7.94 |
Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis to the general public, clinics, and health professionals; and supplies Food Detective, a food sensitivity test. In addition, the company offers My Health Tracker, a health app for tracking symptoms, accessing FoodPrint results, and managing gut health; and CNS Lab, which provides laboratory services for food sensitivity. It serves the government, private hospitals and clinics, reference laboratories, nutritionists, naturopaths, consumers, and functional medicine healthcare practitioners in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc is based in London, the United Kingdom.
One Fleet Place, London, United Kingdom, EC4M 7WS
| Name | Title | Year Born |
|---|---|---|
| Mr. James Cooper B.A., M.Sc. | CEO & Executive Director | 1991 |
| Mr. Ajay Patel A.C.A., L.L.B. | CFO, Secretary & Executive Director | 1964 |
| Mr. Iain Alexander James Logan | Group Financial Controller | 1973 |
| Mr. Prashant Maniar | Managing Director of Omega Dx Asia Pvt Limited | NA |
| Motunrayo Oyegunle | Secretary | NA |
| Mr. Andrew William Shepherd BSc.(Hons) | Global Ambassador - Life President | 1956 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...